FTD Biomarkers Initiative

Where they have been identified, biomarkers enable clinicians and researchers to accurately diagnose diseases and monitor disease progression, both of which are critical to clinical practice and drug development. The current lack of such biomarkers for FTD results in diagnostic delays and errors, and impedes the search for effective treatments.

The FTD Biomarkers Initiative is a major new AFTD funding opportunity focused on this unmet need. Over the next 5 years, AFTD will award up to $5 million to support innovative approaches to the discovery and development of biomarkers that differentiate FTD from other neurodegenerative disorders, discriminate between FTD subtypes, identify underlying molecular pathologies, confirm pharmacodynamic modulation of disease pathways, and track disease progression.

 

Eligibility requirements

  • Investigators at nonprofit academic and medical research institutions or for-profit organizations worldwide.
  • Individual investigators, partnerships, small collaborative groups, or large consortia
Project focus
  • Disorders across the FTD spectrum (behavioral variant FTD, primary progressive aphasia, progressive supranuclear palsy, corticobasal degeneration, and FTD with motor neuron disease)
  • Any underlying pathological mechanism
  • Any approach with potential translational impact
  • All stages of development, from preclinical to advanced

 

Award details

  • Direct costs only
  • Typical budget $250 – 500K; higher or lower requests will also be considered for high impact projects
  • Timeframe 1-2 years; extended timeframes will also be considered for high-impact projects
Data sharing
  •  A commitment to the open exchange of data and results required

To access the RFP for The FTD Biomarkers Initiative, click here.

To further discuss scientific or financial aspects of the proposals, please contact:

Nadine Tatton, PhD, Scientific Director, AFTD

Phone: 267-758-8644/Email: [email protected]

For more information regarding the application process, please contact:

Debra Niehoff, PhD, Research Manager, AFTD

Phone: 267-758-8654/Email: [email protected]

 

FTD Biomarkers Initiative Scientific Advisory Board

~Weninger

Stacie Weninger, PhD, Chair

Executive Director

F-Prime Biomedical Research Initiative

Johnson

Keith Johnson, MD

Professor of Radiology & Neurology

Harvard Medical School

Director, Molecular Neuroimaging,

Massachusetts General Hospital

Boxer

Adam Boxer, MD PhD

Associate Professor of Neurology

Director, AD & FTD Clinical Trials Program,

Memory & Aging Center

University of California, San Francisco

Knopman

David Knopman, MD

Professor of Neurology

Mayo Clinic – Rochester MN

Chair, AFTD Medical Advisory Council

Cha

Jang-ho Cha, MD PhD

Global Translational Medicine

Head, Neuroscience

Novartis Institutes for Biomedical Research (NBIR)

 Mackenzie

Ian Mackenzie, MD

Professor of Pathology & Laboratory Medicine

University  of British Columbia

Dunlop

John Dunlop, PhD

VP & Head, Neuroscience Innovative Medicines

Astra Zeneca

 

Petrucelli

Leonard Petrucelli, MD

Professor of Neuroscience

Mayo Clinic – Jacksonville FL

Forman

Mark Forman, MD PhD

Executive Director, Translational Medicine

Merck

Rohrer

Jonathan Rohrer, MD

Clinical Lecturer & Neurologist

University College London

Principal Investigator, Genetic FTD Initiative (GENFI)

Grossman

Murray Grossman, MD

Professor of Neurology

Director, Penn FTD Center

University of Pennsylvania Medical School

Von Rosentiel

Philipp von Rosenstiel, MD

Senior Medical Director

Neurology, Early Clinical Development

Biogen

Ho

Carole Ho, MD

Chief Medical Officer

Head of Development

Denali Therapeutics

Zetterberg

Henrik Zetterberg, MD PhD

Professor of Neurochemistry

University of Gothenburg